Pharmedium Services, LLC has recalled approximately 12,492 bags of Norepinephrine Bitartrate added to Dextrose Injections due to the drug being subpotent, meaning it may not contain the full strength of the medication required for treatment. These prescription intravenous medications were distributed nationwide to hospitals and healthcare facilities between late 2019 and early 2020. Because these products may not deliver the expected dose of Norepinephrine, patients may not receive the necessary cardiovascular support during critical care.
A subpotent drug may fail to provide the intended therapeutic effect, which for Norepinephrine—a medication used to treat life-threatening low blood pressure—could result in inadequate blood pressure control and poor patient outcomes. No specific injuries or incidents were reported in the recall data.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.